2 Total results for product and free and sample content found
Analyst speculates that risk of pulmonary embolism for a higher unapproved of Xeljanz in arthritis could trigger a label change for the same regimen in the drug's ulcerative colitis indication.
Despite key markets pressures, the rheumatoid arthritis (RA) market is forecast to continue to grow over the next 10 years. Our RA coverage highlights where the opportunities remain, with a detailed look into the future of the RA treatment.
No Records Found
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: